Skip to main content

Advertisement

Table 2 Analysis of T CD4 lymphocyte expression of CD4+CD3+ and CD4+CD25hi, and CD86 activation markers in APCs

From: New strategy for testing efficacy of immunotherapeutic compounds for diabetes in vitro

Treatment Percent of cell phenotypes
  CD4+CD3+ CD4+CD25hi CD11b+CD86+
Medium 24.5 ± 8.2 0.5 ± 0.2 31.8 ± 7.1
Insulin 34.4 ± 3.8 1.2 ± 0.6 44.8 ± 8.6
Insulin + DNAhsp65 49.2 ± 6.8a 6.7 ± 1.6b 77.6 ± 5.1b
Insulin + Hsp65 42.8 ± 4.5a 9.6 ± 3.7b 69.3 ± 6.0b
Insulin + Hsp70 43.1 ± 3.9a 7.7 ± 1.7b 65.0 ± 7.4b
  1. Data are reported as means ± SD for 3 separate experiments
  2. a P < 0.05 compared to insulin group (t-test)
  3. b P < 0.001